Literature DB >> 10806590

A randomized prospective cross-over study of highly purified follicle-stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in women aged 37-41 years.

S Bassil1, C Wyns, J Donnez.   

Abstract

PURPOSE: In the present study, we investigated the benefits of highly purified FSH (H.P. FSH) in comparison with human menopausal gonadotrophin (hMG) in IVF patients aged 37-41 years.
METHODS: Twenty patients experienced within a period of four months both preparations in subsequent cycles through a prospective randomized cross-over design. A standard hormonal treatment consisting of a flare-up protocol using gonadotrophin-releasing hormone agonist (GnRHa) in combination with the same starting dose of H.P. FSH or hMG was used in all cycles.
RESULTS: Cycles stimulated with H.P. FSH resulted in a significantly higher mean number (10.3 +/- 3) of ovocytes retrieved with a significantly shorter (13 +/- 2.3 days) duration of stimulation compared to cycles treated with hMG [mean number of oocytes 7.3 +/- 5 (P < 0.01) and mean duration of stimulation 14.7 +/- 3.9 days (P < 0.02)]. No detrimental effect of basal or exogenous LH on oocyte quality was observed in our study.
CONCLUSIONS: In our experience, H.P. FSH preparations seemed to be more effective than hMG preparations for ovarian stimulation in this group of women aged 37-41 years.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10806590      PMCID: PMC3455161          DOI: 10.1023/a:1009418017662

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  25 in total

1.  Factors affecting the outcome of assisted conception.

Authors:  I Craft
Journal:  Br Med Bull       Date:  1990-07       Impact factor: 4.291

2.  Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression.

Authors:  M C Edelstein; R G Brzyski; G S Jones; S Simonetti; S J Muasher
Journal:  Fertil Steril       Date:  1990-01       Impact factor: 7.329

3.  Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization.

Authors:  R T Scott; G E Hofmann; S Oehninger; S J Muasher
Journal:  Fertil Steril       Date:  1990-08       Impact factor: 7.329

4.  Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression in polycystic ovarian syndrome.

Authors:  T Tanbo; P O Dale; E Kjekshus; E Haug; T Abyholm
Journal:  Fertil Steril       Date:  1990-05       Impact factor: 7.329

5.  Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis.

Authors:  S Daya; J Gunby; E G Hughes; J A Collins; M A Sagle
Journal:  Fertil Steril       Date:  1995-08       Impact factor: 7.329

Review 6.  Treatment of low responders.

Authors:  S J Muasher
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

7.  Delayed occurrence of an LH surge after HCG administration during ovarian stimulation with gonadotrophins: effect of LHRH treatment.

Authors:  F J Rojas; I Moretti-Rojas; J P Balmaceda; R H Asch
Journal:  Hum Reprod       Date:  1989-08       Impact factor: 6.918

8.  Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization.

Authors:  S Daya; J Gunby; E G Hughes; J A Collins; M A Sagle
Journal:  Hum Reprod       Date:  1995-06       Impact factor: 6.918

9.  Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins.

Authors:  E Giudice; C Crisci; A Eshkol; R Papoian
Journal:  Hum Reprod       Date:  1994-12       Impact factor: 6.918

10.  Hypersecretion of luteinising hormone, infertility, and miscarriage.

Authors:  L Regan; E J Owen; H S Jacobs
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.